Victrex (LON:VCT) Sets New 1-Year High – Should You Buy?

Victrex plc (LON:VCT) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 828 and last traded at GBX 816, with a volume of 207575 shares traded. The stock had previously closed at GBX 819.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on VCT. Berenberg Bank boosted their price target on Victrex from GBX 600 to GBX 680 and gave the company a “hold” rating in a research note on Wednesday, July 8th. Canaccord Genuity Group downgraded shares of Victrex to a “buy” rating and set a GBX 725 price objective on the stock. in a research note on Friday, May 15th. UBS Group reissued a “sell” rating and issued a GBX 575 target price on shares of Victrex in a report on Monday, May 11th. Finally, Jefferies Financial Group restated a “hold” rating and issued a GBX 595 target price on shares of Victrex in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of GBX 663.33.

Victrex Stock Performance

The company has a debt-to-equity ratio of 21.30, a current ratio of 2.35 and a quick ratio of 1.99. The stock has a 50-day simple moving average of GBX 676.14 and a 200-day simple moving average of GBX 650.16. The stock has a market cap of £710.95 million, a P/E ratio of -36.43, a PEG ratio of 1.92 and a beta of 0.77.

Victrex (LON:VCT) last posted its earnings results on Monday, May 11th. The company reported GBX 17.20 EPS for the quarter. Victrex had a negative net margin of 6.70% and a negative return on equity of 4.95%. The firm had revenue of £147.10 million during the quarter. Research analysts forecast that Victrex plc will post 73.1078905 earnings per share for the current year.

Victrex Company Profile

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.